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| INTRODUC TI ON
Hepatocellular adenomas (HCA) are rare, hormone-driven benign liver tumours. They mainly develop in young women in their reproductive age. While HCA have an incidence rate around one per million per year in the general population, long-term (>2 years) users of oral contraceptive pills (OCP) have 30-to 40-fold increased risk of developing HCA. [1] [2] [3] Main complications are (potentially lethal)
haemorrhage (15-20%) and malignant transformation to hepatocellular carcinoma (HCC) (5%). [4] [5] [6] HCA of ≥50 mm size are especially at risk for these complications. 4, 5, [7] [8] [9] Hepatocellular adenomas can be classified into subtypes.
Inflammatory HCA (I-HCA) comprise 40% to 55% and are most common in patients with obesity and/or metabolic syndrome. They are associated with prolonged oestrogen exposure. 6 Hepatocyte nuclear factor 1a inactivated HCA (H-HCA) comprise 30% to 40% of HCA and bleed only in rare cases. They are seen in patients with significantly less oestrogen exposure than I-HCA, suggesting a higher oestrogen sensitivity or alternative pathophysiology. 6 Less common are the b-catenin activated adenomas (b-HCA). b-HCA have an increased tendency to transform into HCC and are mostly seen in men.
Half of b-HCA are hybrid b-catenin/I-HCA. 6 b-HCA are diagnosed through immunohistochemical analysis of glutamine synthetase.
Finally, there are unclassified HCA and sonic hedgehog activated HCA, each accounting for 5% to 10% of HCA.
Sex hormones or androgens stimulate both de novo formation as well as growth of HCA. 2, 10 Hence, women using OCP and those using anabolic steroids are particularly at risk of HCA development. Extra gonadal oestrogen is most notably formed by adipose tissue which accounts for 10% to 50% of total oestrogen production. 11 Oestrogen production has been proven to increase with obesity. 12 Vital for a non-invasive management of HCA is that regression can be induced by reduction of circulating oestrogen levels, which occurs naturally after the onset of the menopause, or after substantial weight loss. 13 Hepatocellular adenomas are also known to form in patients with metabolic disorders such as glycogen storage disease (GSD) and hepatocyte nuclear factor 1A maturity onset diabetes of the young (HNF1A-MODY). The incidence, aetiology, behaviour and treatment of these HCA differ from androgen-induced HCA.
The clinical guideline for treatment of benign liver tumours was published by the European Association for the Study of the Liver (EASL) in 2016. 14 It advices an initial conservative and oestrogen level reducing treatment through life style changes in females diagnosed with HCA larger than 50 mm. This reduction is mainly accomplished by weight loss and cessation of all hormonal medication. 15, 16 OCP containing progesterone only are excluded, as this hormone has no role in HCA (patho)physiology. If during follow-up HCA increase significantly in size (>20%), or if after 6 months of wait-and-see policy HCA remain equal to or larger than 50 mm, resection is advised.
It is well established that OCP are the main risk factor for HCA formation and growth, and that HCA show regression after OCP cessation. However, detailed information on exact OCP use in HCA patients, and HCA behaviour after OCP cessation is still lacking. The age of commencement, total duration and age of cessation of OCP
have not yet been observed to influence rate of regression, although research is lacking. Secondly, the current EASL guideline does not take HCA diameter at baseline into account -a 6 month wait-andsee period is advised for all HCA ≥ 50 mm. This period could prove to be frankly too short for regression of large HCA to sub 50 mm size.
The aim of this study was to evaluate the response of HCA after OCP cessation, and to evaluate any factors associated with this response. 
| MATERIAL S AND ME THODS

| Study design and population
| Endpoints
Primary endpoint was HCA response to cessation of OCP as defined by the RECISTv1.1 criteria. Secondary outcomes were HCA-related complications, frequency, indications and outcomes of invasive treatment, and independent predictors of the rate of HCA regression.
| Data collection and definitions
Relevant information was obtained from electronic patient files and a self-designed questionnaire. Obesity was defined by body mass index (BMI) above 30 kg/m 2 and was measured at baseline. One target lesion per patient was followed, defined by the single largest HCA at baseline imaging. These were classified into HCA < 50 mm, 50 ≤ HCA < 100 mm and HCA ≥ 100 mm.
| Data analysis
Continuous variables were described using the median with interquartile range, whereas nominal and ordinal variables were described using totals, frequencies and percentages. 
| RE SULTS
| Study population and baseline characteristics
In total, 267 HCA patients were treated between 2005 and 2018.
Twenty-one patients with concurring GSD, six HNF1A-MODY patients and two male patients diagnosed with HCA were excluded. Of the remaining 238 patients, another 116 were excluded as their OCP use outmatched the inclusion criteria. Thirty-one patients in whom an intervention was performed before the effect of the life style advices could be observed, and 13 patients in whom no observation of OCP cessation was possible, were also excluded, thereby leaving 78 patients available for analysis ( Figure 1 ).
Hepatocellular adenomas were diagnosed at a median age of 32 (27-41) years. About a third of patients had obesity and 11.5% (r s (11) = 0.085, P = 0.53), and neither was total duration of OCP intake (r s (11) = 0.050, P = 0.71) ( Table 1) . 
| HCA response to OCP cessation
TA B L E 1 Baseline characteristics
F I G U R E 2 Spider plot of the relative change of largest HCA diameter from baseline over time for all evaluable patients (n = 78), defined as those with baseline tumour assessments and at least one postbaseline assessment. Lines are colour coded based on overall response. Horizontal dashed lines represent Response Evaluation Criteria In Solid Tumours version 1.1 guideline for partial response (≥30% decrease in target lesion) and progressive disease (≥20% increase in target lesion). Abbreviations: HCA, hepatocellular adenoma; OCP, oral contraceptive pill. Legend: Blue, HCA diameter <50 mm; Orange, HCA diameter >50 mm; Green, HCA diameter >50 mm at baseline, regression to <50 mm size; Red triangle, surgical intervention; Red circle, percutaneous intervention to insufficient patient numbers for HCA subtypes other than I-HCA (Table 2 ).
| HCA-related complications
No HCA-related complications occurred during follow-up. Although two b-HCA were observed, at risk for malignant transformation, there were no cases of actual malignant degeneration to HCC during the follow-up period.
| Interventions
Eighteen patients underwent invasive treatment for HCA, at a median of 8.5 (5.8-14.1) months after diagnosis ( Table 3 
| Factors associated with HCA regression
Rate of HCA regression was analyzed ( Figure 3A) . HCA size at baseline was significantly associate with rate of regression ( Figure 3B ). HCA regression ( Figure 3D ). Duration of OCP intake was not related to the rate of HCA regression. HCA diameter at baseline was significantly related to the rate of HCA regression. Next, a Cox proportional hazard model was performed for univariate analysis of factors influencing regression including the following variables: BMI, total duration of OCP use, age of OCP commencement, age of HCA diagnosis and largest HCA diameter categorized into <50 mm, 50 ≤ HCA<100 mm and ≥100 mm ( 
| D ISCUSS I ON
To our knowledge, this is the first study measuring the radiological HCA response after cessation of OCP using the RECIST criteria. We observed at least 30% regression in almost 40% of HCA patients, and
half of all HCA remained stable after cessation of OCP intake. Only one HCA experienced growth during follow-up imaging. Apart from being effective, this non-invasive therapy was safe as there were no HCA-related complications during the follow-up period. Finally, we demonstrated that HCA diameter was significantly associated with the rate of HCA regression.
Till date, there has been only one report describing HCA regression rate and the timing of HCA resection. Klompenhouwer et al stated that 15% of HCA in their cohort showed regression to 50 mm or smaller after 6 months. This increased to 25% of patients after 1 year. 18 Also, they observed that larger HCA often require more than 6 months to regress to a diameter <50 mm. 18 Their sample size allowed them to exclude a correlation between HCA subtype and response. We were not able to reproduce this in our dataset because of a smaller sample size. Although the authors stated that patients were advised to halt OCP intake and lose weight, it is unclear when OCP intake was exactly stopped in their cohort. This could lead to an underestimation of the effect of OCP cessation and makes estimation of regression time inaccurate.
Apart from including few other HCA subtypes than I-HCA, our study has potential weaknesses. We cannot rule out any residual bias, which is inherent to the retrospective design of our study. We were unable to perform extensive subanalyses in the group with regression to <50 mm in size because of our sample size (n = 49 at baseline may be subject to recall bias. Finally, we were not able to take a possible change in BMI through time into account as it turned out to be rarely reported more than once (at baseline) in the electronic patient files.
It is important to note that not all HCA responded to a reduction of circulating oestrogen levels and that oestrogen sensitivity may possibly vary across subtypes. It has previously been hypothesized that the oestrogen (and general androgen) sensitivity of 
